Aurobindo Pharma is planning to launch first set of oncology, respiratory, complex injectables and topical products in the US in the next three years as part of plans to build a robust specialty products portfolio. The company is also planning to launch first set of biosimilars and vaccines in growth markets during the same period.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
